Annals of Surgical Oncology

, Volume 26, Issue 5, pp 1474–1493 | Cite as

Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma

  • Derek J. Erstad
  • Kenneth K. TanabeEmail author
Hepatobiliary Tumors


Hepatocellular carcinoma (HCC) is a morbid condition for which surgical and ablative therapy are the only options for cure. Nonetheless, over half of patients treated with an R0 resection will develop recurrence. Early recurrences within 2 years after resection are thought to be due to the presence of residual microscopic disease, while late recurrences > 2 years after resection are thought to be de novo metachronous HCCs arising in chronically injured liver tissue. Microvascular invasion (MVI) is defined as the presence of micrometastatic HCC emboli within the vessels of the liver, and is a critical determinant of early recurrence and survival. In this review, we summarize the pathogenesis and clinical relevance of MVI, which correlates with adverse biological features, including high grade, large tumor size, and epithelial–mesenchymal transition. Multiple classification schemas have been proposed to capture the heterogeneous features of MVI that are associated with prognosis. However, currently, MVI can only be determined based on surgical specimens, limiting its clinical applicability. Going forward, advances in axial imaging technologies, molecular characterization of biopsy tissue, and novel serum biomarkers hold promise as future methods for non-invasive MVI detection. Ultimately, MVI status may be used to help clinicians determine treatment plans, particularly with respect to surgical intervention, and to provide more accurate prognostication.



No financial disclosures to declare.


  1. 1.
    White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology. 2017;152(812–20):e5.Google Scholar
  2. 2.
    Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon’s perspective. Ann Surg. 2002;235:466–86.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Colella G, Bottelli R, De Carlis L, Sansalone CV, Rondinara GF, Alberti A, Belli LS, Gelosa F, Iamoni GM, Rampoldi A, De Gasperi A, Corti A, Mazza E, Aseni P, Meroni A, Slim AO, Finzi M, Di Benedetto F, Manochehri F, Follini ML, Ideo G, Forti D. Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization. Transpl Int. 1998;11(Suppl 1):S193–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Lauwers GY, Terris B, Balis UJ, Batts KP, Regimbeau JM, Chang Y, Graeme-Cook F, Yamabe H, Ikai I, Cleary KR, Fujita S, Flejou JF, Zukerberg LR, Nagorney DM, Belghiti J, Yamaoka Y, Vauthey JN, International Cooperative Study Group on Hepatocellular Carcinoma. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol. 2002;26:25–34.CrossRefPubMedGoogle Scholar
  6. 6.
    Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P, Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, Chung AY, Ooi LL, Tan SB. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254:108–13.CrossRefPubMedGoogle Scholar
  8. 8.
    Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet JM, Schwartz ME. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137:850–5.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lee KW, Park JW, Park JB, Kim SJ, Choi SH, Heo JS, Kwon CH, Kim DJ, Han YS, Lee SK, Joh JW. Liver transplantation for hepatocellular carcinoma with bile duct thrombi. Transplant Proc. 2006;38:2093–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10:99–111.CrossRefPubMedGoogle Scholar
  11. 11.
    Hoyos S, Escobar J, Cardona D, Guzman C, Mena A, Osorio G, Perez C, Restrepo JC, Correa G. Factors associated with recurrence and survival in liver transplant patients with HCC—a single center retrospective study. Ann Hepatol. 2015;14:58–63.PubMedGoogle Scholar
  12. 12.
    Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118:277–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhou YM, Cao L, Li B, Zhang RX, Sui CJ, Yin ZF, Yang JM. Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma. Ann Surg Oncol. 2012;19:1700–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Mima K, Hayashi H, Kuroki H, Nakagawa S, Okabe H, Chikamoto A, Watanabe M, Beppu T, Baba H. Epithelial-mesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: clinical significance of transforming growth factor-beta signaling. Oncol Lett. 2013;5:149–54.CrossRefPubMedGoogle Scholar
  15. 15.
    Wan T, Zhang T, Si X, Zhou Y. Overexpression of EMT-inducing transcription factors as a potential poor prognostic factor for hepatocellular carcinoma in Asian populations: a meta-analysis. Oncotarget. 2017;8:59500–8.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 2017;169:1327–41 e23.Google Scholar
  17. 17.
    Sumie S, Nakashima O, Okuda K, Kuromatsu R, Kawaguchi A, Nakano M, Satani M, Yamada S, Okamura S, Hori M, Kakuma T, Torimura T, Sata M. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014;21:1002–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Iguchi T, Shirabe K, Aishima S, Wang H, Fujita N, Ninomiya M, Yamashita Y, Ikegami T, Uchiyama H, Yoshizumi T, Oda Y, Maehara Y. New pathologic stratification of microvascular invasion in hepatocellular carcinoma: predicting prognosis after living-donor liver transplantation. Transplantation. 2015;99:1236–42.CrossRefPubMedGoogle Scholar
  19. 19.
    Feng LH, Dong H, Lau WY, Yu H, Zhu YY, Zhao Y, Lin YX, Chen J, Wu MC, Cong WM. Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2017;143:293–303.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhao H, Chen C, Fu X, Yan X, Jia W, Mao L, Jin H, Qiu Y. Prognostic value of a novel risk classification of microvascular invasion in patients with hepatocellular carcinoma after resection. Oncotarget. 2017;8:5474–86.PubMedGoogle Scholar
  21. 21.
    Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181–200.CrossRefPubMedGoogle Scholar
  22. 22.
    Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261:947–55.CrossRefPubMedGoogle Scholar
  23. 23.
    Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology. 2013;144:1024–30.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kim JW, Ye Q, Forgues M, Chen Y, Budhu A, Sime J, Hofseth LJ, Kaul R, Wang XW. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology. 2004;39:518–27.CrossRefPubMedGoogle Scholar
  25. 25.
    Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol. 2013;20:325–39.CrossRefPubMedGoogle Scholar
  26. 26.
    Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, Yamaoka Y, Belghiti J, Lauwers GY, Poon RT, Abdalla EK. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11:1086–92.CrossRefPubMedGoogle Scholar
  27. 27.
    Munene G, Vauthey JN, Dixon E. Summary of the 2010 AHPBA/SSO/SSAT consensus conference on HCC. Int J Hepatol. 2011;2011:565060.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Tang YH, Wen TF, Chen X. Resection margin in hepatectomy for hepatocellular carcinoma: a systematic review. Hepatogastroenterology. 2012;59:1393–7.PubMedGoogle Scholar
  29. 29.
    Liu N, Wang L, Sun C, Yang L, Sun W, Peng Q. MicroRNA-125b-5p suppresses Brucella abortus intracellular survival via control of A20 expression. BMC Microbiol. 2016;16:171.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kojiro M, Nakashima O. Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors. Semin Liver Dis. 1999;19:287–96.CrossRefPubMedGoogle Scholar
  31. 31.
    Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V. Resection of hepatocellular cancer ≤ 2 cm: results from two Western centers. Hepatology. 2013;57:1426–35.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Izumi R, Shimizu K, Ii T, Yagi M, Matsui O, Nonomura A, Miyazaki I. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 1994;106:720–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Yamashita Y, Tsuijita E, Takeishi K, Fujiwara M, Kira S, Mori M, Aishima S, Taketomi A, Shirabe K, Ishida T, Maehara Y. Predictors for microinvasion of small hepatocellular carcinoma ≤ 2 cm. Ann Surg Oncol. 2012;19:2027–34.CrossRefPubMedGoogle Scholar
  34. 34.
    Jung DH, Hwang S, Lee YJ, Kim KH, Song GW, Ahn CS, Moon DB, Lee SG. Small hepatocellular carcinoma with low tumor marker expression benefits more from anatomical resection than tumors with aggressive biology. Ann Surg. 2019;269:511–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Zhao H, Chen C, Gu S, Yan X, Jia W, Mao L, Qiu Y. Anatomical versus non-anatomical resection for solitary hepatocellular carcinoma without macroscopic vascular invasion: a propensity score matching analysis. J Gastroenterol Hepatol. 2017;32:870–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Marubashi S, Gotoh K, Akita H, Takahashi H, Ito Y, Yano M, Ishikawa O, Sakon M. Anatomical versus non-anatomical resection for hepatocellular carcinoma. Br J Surg. 2015;102:776–84.CrossRefPubMedGoogle Scholar
  37. 37.
    Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007;245:36–43.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Maeda T, Takenaka K, Taguchi K, Kajiyama K, Shirabe K, Shimada M, Honda H, Sugimachi K. Small hepatocellular carcinoma with minute satellite nodules. Hepatogastroenterology. 2000;47:1063–6.PubMedGoogle Scholar
  39. 39.
    Maeda T, Takenaka K, Adachi E, Matsumata T, Shirabe K, Honda H, Sugimachi K, Tsuneyoshi M. Small hepatocellular carcinoma of single nodular type: a specific reference to its surrounding cancerous area undetected radiologically and macroscopically. J Surg Oncol. 1995;60:75–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Fukushima N, Sakamoto M. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95:1931–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Sasaki A, Kai S, Iwashita Y, Hirano S, Ohta M, Kitano S. Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer. 2005;103:299–306.CrossRefPubMedGoogle Scholar
  42. 42.
    Curley SA. Radiofrequency ablation leads to excellent local tumor control and durable longterm survival in specific subsets of early stage HCC patients confirming to the Milan criteria. Ann Surg. 2010;252:913–4.CrossRefPubMedGoogle Scholar
  43. 43.
    Chen MS, Li JQ, Liang HH, Lin XJ, Guo RP, Zheng Y, Zhang YQ. Comparison of effects of percutaneous radiofrequency ablation and surgical resection on small hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi. 2005;85:80–3.PubMedGoogle Scholar
  44. 44.
    Lu MD, Kuang M, Liang LJ, Xie XY, Peng BG, Liu GJ, Li DM, Lai JM, Li SQ. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi. 2006;86:801–5 (in Chinese).PubMedGoogle Scholar
  45. 45.
    Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252:903–12.CrossRefPubMedGoogle Scholar
  46. 46.
    Feng K, Yan J, Li X, Xia F, Ma K, Wang S, Bie P, Dong J. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57:794–802.CrossRefPubMedGoogle Scholar
  47. 47.
    Cho YK. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2011;254:838–9 author reply 9.CrossRefPubMedGoogle Scholar
  48. 48.
    Liu PH, Hsu CY, Hsia CY, Lee YH, Huang YH, Chiou YY, Lin HC, Huo TI. Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma ≤ 2 cm in a propensity score model. Ann Surg. 2016;263:538–45.CrossRefPubMedGoogle Scholar
  49. 49.
    Liao M, Huang J, Wu H, Zeng Y. Shall we take a second thought before applying radiofrequency ablation for resectable HCC ≤ 2 cm? Hepatobiliary Surg Nutr. 2014;3:109–11.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Ueno M, Hayami S, Shigekawa Y, Kawai M, Hirono S, Okada K, Tamai H, Shingaki N, Mori Y, Ichinose M, Yamaue H. Prognostic impact of surgery and radiofrequency ablation on single nodular HCC 5 cm: cohort study based on serum HCC markers. J Hepatol. 2015;63:1352–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Minami Y, Minami T, Hagiwara S, Ida H, Ueshima K, Nishida N, Murakami T, Kudo M. Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma. Eur Radiol. 2018;28(5):1986–93.CrossRefPubMedGoogle Scholar
  52. 52.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.CrossRefPubMedGoogle Scholar
  53. 53.
    Ryu SH, Chung YH, Lee H, Kim JA, Shin HD, Min HJ, Seo DD, Jang MK, Yu E, Kim KW. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology. 2008;47:929–36.CrossRefPubMedGoogle Scholar
  54. 54.
    Bui-Nguyen TM, Pakala SB, Sirigiri RD, Xia W, Hung MC, Sarin SK, Kumar V, Slagle BL, Kumar R. NF-kappaB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx. Oncogene. 2010;29:1179–89.CrossRefPubMedGoogle Scholar
  55. 55.
    Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y, Wang HY, Cheng SQ, Xie D, Wang XF. TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22:291–303.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Omichi K, Shindoh J, Yamamoto S, Matsuyama Y, Akamatsu N, Arita J, Kaneko J, Sakamoto Y, Hasegawa K, Kokudo N. Postoperative outcomes for patients with non-B non-C hepatocellular carcinoma: a subgroup analysis of patients with a history of hepatitis B infection. Ann Surg Oncol. 2015;22(Suppl 3):S1034–40.CrossRefPubMedGoogle Scholar
  57. 57.
    Lei Z, Li J, Wu D, Xia Y, Wang Q, Si A, Wang K, Wan X, Lau WY, Wu M, Shen F. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria. JAMA Surg. 2016;151:356–63.CrossRefPubMedGoogle Scholar
  58. 58.
    Li Z, Lei Z, Xia Y, Li J, Wang K, Zhang H, Wan X, Yang T, Zhou W, Wu M, Pawlik TM, Lau WY, Shen F. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related hepatocellular carcinoma. JAMA Surg. 2018;153:e182721.CrossRefPubMedGoogle Scholar
  59. 59.
    Sun JJ, Wang K, Zhang CZ, Guo WX, Shi J, Cong WM, Wu MC, Lau WY, Cheng SQ. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann Surg Oncol. 2016;23:1344–51.CrossRefPubMedGoogle Scholar
  60. 60.
    Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH, Lin XJ, Xu L, Shi M, Zheng L, Chen MS, Guo RP. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (Lond). 2018;38:61.CrossRefGoogle Scholar
  61. 61.
    Ye JZ, Chen JZ, Li ZH, Bai T, Chen J, Zhu SL, Li LQ, Wu FX. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion. World J Gastroenterol. 2017;23:7415–24.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Liu C, Sun L, Xu J, Zhao Y. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma. World J Surg Oncol. 2016;14:100.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Wang YY, Wang LJ, Xu D, Liu M, Wang HW, Wang K, Zhu X, Xing BC. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion. HPB (Oxford). 2018. Scholar
  64. 64.
    Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220:416–27.CrossRefPubMedGoogle Scholar
  65. 65.
    Bhoori S, Mazzaferro V. Current challenges in liver transplantation for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2014;28:867–79.CrossRefPubMedGoogle Scholar
  66. 66.
    Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017;3:493–500.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018;18:1206–13.CrossRefPubMedGoogle Scholar
  68. 68.
    Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, Settmacher U, Neuhaus P. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–6.CrossRefPubMedGoogle Scholar
  69. 69.
    Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, Quan D, McAllister V, Ghent C, Levstik M, McLean C, Chakrabarti S, Garcia B, Driman DK. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl. 2007;13:543–51.CrossRefPubMedGoogle Scholar
  70. 70.
    Bhangui P, Allard MA, Vibert E, Cherqui D, Pelletier G, Cunha AS, Guettier C, Vallee JC, Saliba F, Bismuth H, Samuel D, Castaing D, Adam R. Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes? Ann Surg. 2016;264:155–63.CrossRefPubMedGoogle Scholar
  71. 71.
    Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology. 2016;64:2077–88.CrossRefPubMedGoogle Scholar
  72. 72.
    Viveiros A, Zoller H, Finkenstedt A. Hepatocellular carcinoma: when is liver transplantation oncologically futile? Transl Gastroenterol Hepatol. 2017;2:63.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg. 2007;245:435–42.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, Chan BK, Matcuk GR, Barry CT, Chang HY, Kuo MD. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol. 2007;25:675–80.CrossRefPubMedGoogle Scholar
  75. 75.
    Banerjee S, Wang DS, Kim HJ, Sirlin CB, Chan MG, Korn RL, Rutman AM, Siripongsakun S, Lu D, Imanbayev G, Kuo MD. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology. 2015;62:792–800.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Chou CT, Chen RC, Lin WC, Ko CJ, Chen CB, Chen YL. Prediction of microvascular invasion of hepatocellular carcinoma: preoperative CT and histopathologic correlation. AJR Am J Roentgenol. 2014;203:W253–9.CrossRefPubMedGoogle Scholar
  77. 77.
    Wu TH, Hatano E, Yamanaka K, Seo S, Taura K, Yasuchika K, Fujimoto Y, Nitta T, Mizumoto M, Mori A, Okajima H, Kaido T, Uemoto S. A non-smooth tumor margin on preoperative imaging predicts microvascular invasion of hepatocellular carcinoma. Surg Today. 2016;46:1275–81.CrossRefPubMedGoogle Scholar
  78. 78.
    Lee S, Kim SH, Lee JE, Sinn DH, Park CK. Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. J Hepatol. 2017;67:526–34.CrossRefPubMedGoogle Scholar
  79. 79.
    Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM. Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol. 2017;27:4472–81.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Zheng J, Chakraborty J, Chapman WC, Gerst S, Gonen M, Pak LM, Jarnagin WR, DeMatteo RP, Do RKG, Simpson AL, Hepatopancreatobiliary Service in the Department of Surgery of the Memorial Sloan Kettering Cancer C, Research Staff in the Department of Surgery at Washington University School of M. Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Using Quantitative Image Analysis. J Am Coll Surg 2017;225:778–88 e1.Google Scholar
  81. 81.
    Geninatti Crich S, Cutrin JC, Lanzardo S, Conti L, Kalman FK, Szabo I, Lago NR, Iolascon A, Aime S. Mn-loaded apoferritin: a highly sensitive MRI imaging probe for the detection and characterization of hepatocarcinoma lesions in a transgenic mouse model. Contrast Media Mol Imaging. 2012;7:281–8.CrossRefPubMedGoogle Scholar
  82. 82.
    Li YW, Chen ZG, Zhao ZS, Li HL, Wang JC, Zhang ZM. Preparation of magnetic resonance probes using one-pot method for detection of hepatocellular carcinoma. World J Gastroenterol. 2015;21:4275–83.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Shen JM, Li XX, Fan LL, Zhou X, Han JM, Jia MK, Wu LF, Zhang XX, Chen J. Heterogeneous dimer peptide-conjugated polylysine dendrimer-Fe3O4 composite as a novel nanoscale molecular probe for early diagnosis and therapy in hepatocellular carcinoma. Int J Nanomedicine. 2017;12:1183–200.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Kavanaugh G, Williams J, Morris AS, Nickels ML, Walker R, Koglin N, Stephens AW, Washington MK, Geevarghese SK, Liu Q, Ayers D, Shyr Y, Manning HC. Utility of [18F]FSPG PET to image hepatocellular carcinoma: first clinical evaluation in a US population. Mol Imaging Biol. 2016;18:924–34.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Schlichtemeier SM, Pang TC, Williams NE, Gill AJ, Smith RC, Samra JS, Lam VW, Hollands M, Richardson AJ, Pleass HC, Nozawa S, Albania M, Hugh TJ. A pre-operative clinical model to predict microvascular invasion and long-term outcome after resection of hepatocellular cancer: the Australian experience. Eur J Surg Oncol. 2016;42:1576–83.CrossRefPubMedGoogle Scholar
  86. 86.
    Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K, Inoue Y, Uchiyama K. Outcomes and predictors of microvascular invasion of solitary hepatocellular carcinoma. Hepatol Res. 2014;44:846–53.CrossRefPubMedGoogle Scholar
  87. 87.
    Yu Y, Song J, Zhang R, Liu Z, Li Q, Shi Y, Chen Y, Chen J. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict microvascular invasion in patients with hepatocellular carcinoma. Oncotarget. 2017;8:79722–30.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Liu M, Wang L, Zhu H, Rong W, Wu F, Liang S, Xu N, Wu J. A preoperative measurement of serum microRNA-125b may predict the presence of microvascular invasion in hepatocellular carcinomas patients. Transl Oncol. 2016;9:167–72.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Minguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol. 2011;55:1325–31.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Xu XF, Yu JJ, Xing H, Shen F, Yang T. How to better predict microvascular invasion and recurrence of hepatocellular carcinoma. J Hepatol. 2017;67:1119–20.CrossRefPubMedGoogle Scholar
  91. 91.
    Cucchetti A, Piscaglia F, Grigioni AD, Ravaioli M, Cescon M, Zanello M, Grazi GL, Golfieri R, Grigioni WF, Pinna AD. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol. 2010;52:880–8.CrossRefPubMedGoogle Scholar
  92. 92.
    Kobayashi T, Aikata H, Honda F, Nakano N, Nakamura Y, Hatooka M, Morio K, Morio R, Fukuhara T, Masaki K, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ohdan H, Awai K, Chayama K. Preoperative fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for prediction of microvascular invasion in small hepatocellular carcinoma. J Comput Assist Tomogr. 2016;40:524–30.CrossRefPubMedGoogle Scholar
  93. 93.
    Shirabe K, Toshima T, Kimura K, Yamashita Y, Ikeda T, Ikegami T, Yoshizumi T, Abe K, Aishima S, Maehara Y. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int. 2014;34:937–41.CrossRefPubMedGoogle Scholar
  94. 94.
    Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology. 2005;129:1375–83.CrossRefPubMedGoogle Scholar
  95. 95.
    Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007;67:2497–507.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology. 2008;47:1557–66.CrossRefPubMedGoogle Scholar
  97. 97.
    Sun C, Sun L, Jiang K, Gao DM, Kang XN, Wang C, Zhang S, Huang S, Qin X, Li Y, Liu YK. NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. Int J Biochem Cell Biol. 2013;45:1099–108.CrossRefGoogle Scholar
  98. 98.
    Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia XF, Sun X, Li GG, Hu QD, Fu QH, Liang TB. Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res. 2016;76:818–30.CrossRefPubMedGoogle Scholar
  99. 99.
    Wu TJ, Chang SS, Li CW, Hsu YH, Chen TC, Lee WC, Yeh CT, Hung MC. Severe hepatitis promotes hepatocellular carcinoma recurrence via NF-kappaB pathway-mediated epithelial-mesenchymal transition after resection. Clin Cancer Res. 2016;22:1800–12.CrossRefPubMedGoogle Scholar
  100. 100.
    Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW, Wang Z, Fan J, Dai Z, Zhou J. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3 K/Akt/GSK-3beta/Snail signaling. Cancer Lett. 2015;358:124–35.CrossRefPubMedGoogle Scholar
  101. 101.
    Huang W, Chen Z, Zhang L, Tian D, Wang D, Fan D, Wu K, Xia L. Interleukin-8 induces expression of FOXC1 to promote transactivation of CXCR1 and CCL2 in hepatocellular carcinoma cell lines and formation of metastases in mice. Gastroenterology. 2015;149(1053–67):e14.Google Scholar
  102. 102.
    Xiao S, Chang RM, Yang MY, Lei X, Liu X, Gao WB, Xiao JL, Yang LY. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition. Hepatology. 2016;63:1256–71.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, Kubo T, Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 2005;24:6406–17.CrossRefPubMedGoogle Scholar
  104. 104.
    Lim SO, Gu JM, Kim MS, Kim HS, Park YN, Park CK, Cho JW, Park YM, Jung G. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology. 2008;135(2128–40):2140.e1–8.Google Scholar
  105. 105.
    Ogunwobi OO, Puszyk W, Dong HJ, Liu C. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS ONE. 2013;8:e63765.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Xie Q, Chen L, Shan X, Shan X, Tang J, Zhou F, Chen Q, Quan H, Nie D, Zhang W, Huang AL, Tang N. Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway. Int J Cancer. 2014;135:635–46.CrossRefPubMedGoogle Scholar
  107. 107.
    Wang ZC, Gao Q, Shi JY, Guo WJ, Yang LX, Liu XY, Liu LZ, Ma LJ, Duan M, Zhao YJ, Wu YN, Gao DM, Wang XY, Shi GM, Ding ZB, Ke AW, Tang QQ, Cao Y, Zhou J, Fan J. Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition. Hepatology. 2015;62:1201–14.CrossRefPubMedGoogle Scholar
  108. 108.
    Wang F, Feng Y, Li P, Wang K, Feng L, Liu YF, Huang H, Guo YB, Mao QS, Xue WJ. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma. Oncotarget. 2016;7:4279–97.PubMedGoogle Scholar
  109. 109.
    He G, Hu S, Zhang D, Wu P, Zhu X, Xin S, Lu G, Ding Y, Liang L. Hypermethylation of FOXD3 suppresses cell proliferation, invasion and metastasis in hepatocellular carcinoma. Exp Mol Pathol. 2015;99:374–82.CrossRefPubMedGoogle Scholar
  110. 110.
    Li CP, Cai MY, Jiang LJ, Mai SJ, Chen JW, Wang FW, Liao YJ, Chen WH, Jin XH, Pei XQ, Guan XY, Zeng MS, Xie D. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma. Carcinogenesis. 2016;37:557–66.CrossRefPubMedGoogle Scholar
  111. 111.
    Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009;275:44–53.CrossRefPubMedGoogle Scholar
  112. 112.
    Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut. 2012;61:278–89.CrossRefPubMedGoogle Scholar
  113. 113.
    Yan Y, Luo YC, Wan HY, Wang J, Zhang PP, Liu M, Li X, Li S, Tang H. MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelial-mesenchymal transition and adhesion in hepatoma cells. Hepatology. 2013;57:667–77.CrossRefPubMedGoogle Scholar
  114. 114.
    Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng X, Zhu Z, Jiao H, Lin J, Jiang K, Ding L, Zhang H, Cheng L, Fu H, Song Y, Jiang Y, Liu J, Wang R, Du N, Ye Q. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest. 2013;123:630–45.PubMedPubMedCentralGoogle Scholar
  115. 115.
    Brockhausen J, Tay SS, Grzelak CA, Bertolino P, Bowen DG, d’Avigdor WM, Teoh N, Pok S, Shackel N, Gamble JR, Vadas M, McCaughan GW. miR-181a mediates TGF-beta-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer. Liver Int. 2015;35:240–53.CrossRefPubMedGoogle Scholar
  116. 116.
    Ning BF, Ding J, Liu J, Yin C, Xu WP, Cong WM, Zhang Q, Chen F, Han T, Deng X, Wang PQ, Jiang CF, Zhang JP, Zhang X, Wang HY, Xie WF. Hepatocyte nuclear factor 4alpha-nuclear factor-kappaB feedback circuit modulates liver cancer progression. Hepatology. 2014;60:1607–19.CrossRefPubMedGoogle Scholar
  117. 117.
    Shih YT, Wang MC, Zhou J, Peng HH, Lee DY, Chiu JJ. Endothelial progenitors promote hepatocarcinoma intrahepatic metastasis through monocyte chemotactic protein-1 induction of microRNA-21. Gut. 2015;64:1132–47.CrossRefPubMedGoogle Scholar
  118. 118.
    Yang YM, Lee WH, Lee CG, An J, Kim ES, Kim SH, Lee SK, Lee CH, Dhanasekaran DN, Moon A, Hwang S, Lee SJ, Park JW, Kim KM, Kim SG. Galpha12 gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma. Oncogene. 2015;34:2910–21.CrossRefPubMedGoogle Scholar
  119. 119.
    Kan H, Guo W, Huang Y, Liu D. MicroRNA-520 g induces epithelial-mesenchymal transition and promotes metastasis of hepatocellular carcinoma by targeting SMAD7. FEBS Lett. 2015;589:102–9.CrossRefPubMedGoogle Scholar
  120. 120.
    Zhou JN, Zeng Q, Wang HY, Zhang B, Li ST, Nan X, Cao N, Fu CJ, Yan XL, Jia YL, Wang JX, Zhao AH, Li ZW, Li YH, Xie XY, Zhang XM, Dong Y, Xu YC, He LJ, Yue W, Pei XT. MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. Hepatology. 2015;62:801–15.CrossRefPubMedGoogle Scholar
  121. 121.
    Yang J, Liu X, Yuan X, Wang Z. miR-99b promotes metastasis of hepatocellular carcinoma through inhibition of claudin 11 expression and may serve as a prognostic marker. Oncol Rep. 2015;34:1415–23.CrossRefPubMedGoogle Scholar
  122. 122.
    Wang Y, Sun B, Zhao X, Zhao N, Sun R, Zhu D, Zhang Y, Li Y, Gu Q, Dong X, Wang M, An J. Twist1-related miR-26b-5p suppresses epithelial-mesenchymal transition, migration and invasion by targeting SMAD1 in hepatocellular carcinoma. Oncotarget. 2016;7:24383–401.PubMedPubMedCentralGoogle Scholar
  123. 123.
    Sandbothe M, Buurman R, Reich N, Greiwe L, Vajen B, Gurlevik E, Schaffer V, Eilers M, Kuhnel F, Vaquero A, Longerich T, Roessler S, Schirmacher P, Manns MP, Illig T, Schlegelberger B, Skawran B. The microRNA-449 family inhibits TGF-beta-mediated liver cancer cell migration by targeting SOX4. J Hepatol. 2017;66:1012–21.CrossRefPubMedGoogle Scholar
  124. 124.
    Deng L, Tang J, Yang H, Cheng C, Lu S, Jiang R, Sun B. MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway. Oncogene. 2017;36:3976–85.CrossRefPubMedGoogle Scholar
  125. 125.
    Battistelli C, Cicchini C, Santangelo L, Tramontano A, Grassi L, Gonzalez FJ, de Nonno V, Grassi G, Amicone L, Tripodi M. The Snail repressor recruits EZH2 to specific genomic sites through the enrollment of the lncRNA HOTAIR in epithelial-to-mesenchymal transition. Oncogene. 2017;36:942–55.CrossRefPubMedGoogle Scholar
  126. 126.
    Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Wang TT, Zhou CC, Wang SB, Wang YZ, Yang Y, Yang N, Zhou WP, Yang GS, Sun SH. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25:666–81.CrossRefPubMedGoogle Scholar
  127. 127.
    Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Deng X, Chen H, Shen B, Peng C, Li H, Zhan Q, Zhu Z. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene. 2016;35:1575–84.CrossRefPubMedGoogle Scholar
  128. 128.
    Yan X, Zhang D, Wu W, Wu S, Qian J, Hao Y, Yan F, Zhu P, Wu J, Huang G, Huang Y, Luo J, Liu X, Liu B, Chen X, Du Y, Chen RS, Fan Z. Mesenchymal stem cells promote hepatocarcinogenesis via lncRNA-MUF interaction with ANXA2 and miR-34a. Cancer Res. 2017;77:6704–16.CrossRefPubMedGoogle Scholar
  129. 129.
    Li C, Lu L, Feng B, Zhang K, Han S, Hou D, Chen L, Chu X, Wang R. The lincRNA-ROR/miR-145 axis promotes invasion and metastasis in hepatocellular carcinoma via induction of epithelial-mesenchymal transition by targeting ZEB2. Sci Rep. 2017;7:4637.CrossRefPubMedPubMedCentralGoogle Scholar
  130. 130.
    Liu F, Yuan JH, Huang JF, Yang F, Wang TT, Ma JZ, Zhang L, Zhou CC, Wang F, Yu J, Zhou WP, Sun SH. Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a. Oncogene. 2016;35:5422–34.CrossRefPubMedGoogle Scholar
  131. 131.
    Zhao H, Hua Y, Lu Z, Gu S, Zhu L, Ji Y, Qiu Y, Dai T, Jin H. Prognostic value and preoperative predictors of microvascular invasion in solitary hepatocellular carcinoma ≤ 5 cm without macrovascular invasion. Oncotarget. 2017;8:61203–14.PubMedPubMedCentralGoogle Scholar
  132. 132.
    Liu J, Zhu Q, Li Y, Qiao GL, Xu C, Guo DL, Tang J, Duan R. Microvascular invasion and positive HB e antigen are associated with poorer survival after hepatectomy of early hepatocellular carcinoma: a retrospective cohort study. Clin Res Hepatol Gastroenterol. 2018;42:330–8.CrossRefPubMedGoogle Scholar
  133. 133.
    Park YK, Song SK, Kim BW, Park SK, Chung CW, Wang HJ. Prognostic significance of microvascular invasion in tumor stage for hepatocellular carcinoma. World J Surg Oncol. 2017;15:225.CrossRefPubMedPubMedCentralGoogle Scholar
  134. 134.
    Hou YF, Wei YG, Yang JY, Wen TF, Xu MQ, Yan LN, Li B, Chen KF. Microvascular invasion patterns affect survival in hepatocellular carcinoma patients after second hepatectomy. J Surg Res. 2016;200:82–90.CrossRefPubMedGoogle Scholar
  135. 135.
    Jang SY, Park SY, Lee HW, Choi YK, Park KG, Yoon GS, Tak WY, Kweon YO, Hur K, Lee WK. The combination of periostin overexpression and microvascular invasion is related to a poor prognosis for hepatocellular carcinoma. Gut Liver. 2016;10:948–54.CrossRefPubMedPubMedCentralGoogle Scholar
  136. 136.
    Du M, Chen L, Zhao J, Tian F, Zeng H, Tan Y, Sun H, Zhou J, Ji Y. Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma. BMC Cancer. 2014;14:38.CrossRefPubMedPubMedCentralGoogle Scholar
  137. 137.
    Hung HH, Lei HJ, Chau GY, Su CW, Hsia CY, Kao WY, Lui WY, Wu WC, Lin HC, Wu JC. Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection. J Gastrointest Surg. 2013;17:702–11.CrossRefPubMedGoogle Scholar
  138. 138.
    Chan SC, Fan ST, Chok KS, Cheung TT, Chan AC, Fung JY, Poon RT, Lo CM. Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion. Hepatol Int. 2012;6:646–56.CrossRefPubMedGoogle Scholar
  139. 139.
    Fan ST, Poon RT, Yeung C, Lam CM, Lo CM, Yuen WK, Ng KK, Liu CL, Chan SC. Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria. Br J Surg. 2011;98:1292–300.CrossRefPubMedGoogle Scholar
  140. 140.
    Kim H, Park MS, Park YN, Kim H, Kim KS, Choi JS, Ahn SH, Han KH, Kim MJ, Kim KW. Preoperative radiologic and postoperative pathologic risk factors for early intra-hepatic recurrence in hepatocellular carcinoma patients who underwent curative resection. Yonsei Med J. 2009;50:789–95.CrossRefPubMedPubMedCentralGoogle Scholar
  141. 141.
    Wang CC, Iyer SG, Low JK, Lin CY, Wang SH, Lu SN, Chen CL. Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2009;16:1832–42.CrossRefPubMedGoogle Scholar
  142. 142.
    Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, Watanabe Y, Kojiro M, Sata M. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol. 2008;15:1375–82.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of SurgeryMassachusetts General HospitalBostonUSA
  2. 2.Division of Surgical OncologyMassachusetts General HospitalBostonUSA

Personalised recommendations